Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Compass PathwaysCMPS +6.20%31 EV-to-OCF is -9.87 as of Aug. 12, 2026. GuruFocus rates CMPS with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 683 Healthcare Providers & Services companies, Compass Pathways ranks better than 83.16% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Compass Pathways's Enterprise Value is $1,590.47 Mil.
Compass Pathways's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-161.14 Mil. Therefore, Compass Pathways's EV-to-OCF for today is -9.87.
The historical rank and industry rank for Compass Pathways's EV-to-OCF or its related term are showing as below:
CMPS'
s EV-to-OCF Range Over the Past 10 Years
Min: -10.08 Med: 0 Max: -9.15
Current: -9.87
During the past 8 years, the highest EV-to-OCF of Compass Pathways was -9.15. The lowest was -10.08. And the median was .
CMPS's EV-to-OCF is ranked better than 83.16% of 683
companies
in the Healthcare Providers & Services industry
Industry Median: 8.91
vs CMPS: -9.87
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Compass Pathways's PE Ratio (TTM) for today is calculated as:
Compass Pathways's share price for today is $14.235.
Compass Pathways's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.620.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Compass Pathways EV-to-OCF Related Terms
Compass Pathways EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Compass Pathways's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Compass Pathways's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Compass Pathways EV-to-OCF vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Compass Pathways's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Compass Pathways's EV-to-OCF falls into.
Compass Pathways's current Enterprise Value is $1,590.47 Mil.
Compass Pathways's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-161.14 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Compass Pathways (CMPS) has a EV-to-OCF of -9.87 as of Aug. 12, 2026. According to the industry distribution chart, Compass Pathways ranks #115 out of 683 companies in the Healthcare Providers & Services industry, placing it in the top 16.8%.
Is Compass Pathways' EV-to-OCF too high?
Compass Pathways' current EV-to-OCF is -9.87. Based on the distribution chart, Compass Pathways ranks #115 out of 683 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Compass Pathways has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Compass Pathways' EV-to-OCF compare to ARDT and HCSG?
According to the Healthcare Providers & Services industry distribution chart, Compass Pathways ranks #115 out of 683 companies for EV-to-OCF. This places Compass Pathways in the top 17% of its industry — outperforming the majority of peers. The industry median EV-to-OCF is 8.91. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Healthcare Providers & Services company?
The median EV-to-OCF among Healthcare Providers & Services companies is 8.91, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median EV-to-OCF is 8.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Compass Pathways's current EV-to-OCF is -9.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compass Pathways stock overvalued right now?
Compass Pathways (CMPS) has a current EV-to-OCF of -9.87. The current EV-to-OCF is -9.87. Compass Pathways' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Compass Pathways (CMPS), the current EV-to-OCF is -9.87 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
31GF Score
Get the complete analysis for CMPS
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMPS has been successfully added to your 
